Study: Chemotherapy to Treat Glioblastoma May Be More Effective During Morning
April 8th 2021Patients with glioblastoma receiving temozolomide in the morning had an average overall survival of about 17 months, compared to an average overall survival of approximately 13.5 months for those taking the drug in the evening.
Read More
HOPA 2021: Virtual Format Offers More Opportunities Than Ever
April 8th 2021Although many attendees and presenters are looking forward to returning to in-person conferences in the future, Anne Krolikowski said the virtual format of their upcoming conference allows even more people to attend.
Read More
Study: Lower Income Neighborhoods Experience Higher COVID-19 Impact
April 8th 2021Indicators of the COVID-19 pandemic’s impact, including testing rates, positivity ratio, case rates by overall population, and deaths, are clustered by neighborhood, with low-income and predominantly minority communities experiencing worse outcomes.
Read More
Diet, Exercise With Chemotherapy Leads to Increased Survival in Youth With Leukemia
April 7th 2021According to previous studies, youth who are obese when they begin chemotherapy are more than twice as likely to have remaining cancer cells after 1 month of treatment compared to their lean counterparts.
Read More
Oncology Pharmacists Are Essential Members of Care Teams to Handle Drug Shortages, Errors
April 6th 2021The oncology space has seen rapid growth in the last decade, with new approvals and indications necessitating expertise in areas such as medication use, safe practices, and reimbursement practices.
Read More
Study: Vitamin D Deficiency in Patients With Lupus Linked to Metabolic Disorders
April 6th 2021Patients with lupus who have lower vitamin D levels are more likely to have metabolic syndrome and insulin resistance, both of which are linked to heart disease, according to a new study published in Rheumatology.
Read More
Personalizing Neoadjuvant and Adjuvant HER2-Targeted Therapy for Breast Cancer
April 6th 2021Understanding breast cancer and which patients may be more vulnerable to long-term treatment effects and which patients may benefit most, can help oncologists design the best personalized neoadjuvant and adjuvant human epidermal growth factor receptor 2 (HER2)-targeted therapy.
Read More